JAMA Dermatology

<jats:sec><jats:title>Importance</jats:title><jats:p>Prurigo nodularis (PN) is a chronic and debilitating skin condition, characterized by intense itch with multiple nodular lesions. Nemolizumab demonstrated significant improvements in itch and skin nodules in adults with moderate to severe PN in a previous 16-week phase 3 study (OLYMPIA 2).</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To assess the efficacy and occurrence of adverse events in adults with moderate to severe PN treated with nemolizumab vs those receiving placebo.</jats:p></jats:sec><jats:sec><jats:title>Design, Setting, and Participants</jats:title><jats:p>OLYMPIA 1 was a multicenter, placebo-controlled, phase 3 randomized clinical trial, conducted from August 2020 to March 2023 at 77 centers across 10 countries in adults with moderate to severe PN (at least 20 nodules and an Investigator’s Global Assessment [IGA] score ≥3) and Peak Pruritus Numerical Rating Scale (PP-NRS) score of at least 7.0; consisted of screening (up to 4 weeks), 24-week treatment, and 8-week follow-up periods.</jats:p></jats:sec><jats:sec><jats:title>Interventions</jats:title><jats:p>Patients were randomized (2:1) to nemolizumab monotherapy, 30 mg or 60 mg (depending on baseline weight of less than 90 kg vs 90 kg or greater, respectively), or matching placebo administered every 4 weeks for 24 weeks.</jats:p></jats:sec><jats:sec><jats:title>Main Outcomes and Measures</jats:title><jats:p>The primary end points were the proportion of patients with itch response (≥4-point improvement from baseline in weekly average PP-NRS) and IGA success (score of 0/1 [clear/almost clear] and 2-grade or more improvement from baseline) at week 16.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of 286 patients (mean [SD] age, 57.5 [13.0] years; mean [SD] body weight, 85.0 [20.7] kg; 166 [58.0%] female), 190 were randomized to receive nemolizumab, and 96 were randomized to placebo. A significantly greater proportion of patients assigned to nemolizumab vs placebo achieved itch response (111/190 [58.4%] vs 16/96 [16.7%]; Δ, 40.1% [95% CI, 29.4%-50.8%]; <jats:italic>P</jats:italic> &amp;amp;lt; .001) and IGA success (50/190 [26.3%] vs 7/96 [7.3%]; Δ, 14.6% [95% CI, 6.7%-22.6%]; <jats:italic>P</jats:italic> = .003) at week 16. At week 24, the proportion of patients with itch response was 58.3% vs 20.4% (Δ, 38.7% [95% CI, 27.5%-49.9%]) in the ad hoc analysis, and IGA success was 58/190 (30.5%) vs 9/96 (9.4%) (Δ, 19.2% [95% CI, 10.3%-28.1%]) in the nemolizumab-treated vs placebo group. During the treatment period, 134 patients (71.7%) receiving nemolizumab vs 62 patients (65.3%) receiving placebo had at least 1 adverse event; most events were of mild to moderate severity.</jats:p></jats:sec><jats:sec><jats:title>Conclusions and Relevance</jats:title><jats:p>In this randomized clinical trial, nemolizumab monotherapy led to clinically meaningful and statistically significant improvements in core signs and symptoms of PN.</jats:p></jats:sec><jats:sec><jats:title>Trial Registration</jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/study/NCT04501666">NCT04501666</jats:ext-link></jats:p></jats:sec>

Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus.

J Am Acad Dermatol

European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo.

J Eur Acad Dermatol Venereol

Ethnic differences and comorbidities of 909 prurigo nodularis patients.

Real-world prevalence of prurigo nodularis and burden of associated diseases.

J Invest Dermatol

Chronic prurigo including prurigo nodularis: new insights and treatments.

Am J Clin Dermatol

Chronic prurigo.

Br J Dermatol

Chronic nodular prurigo: clinical profile and burden—a European cross-sectional study.

Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.

Expert Rev Clin Pharmacol

Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues.

Front Med (Lausanne)

The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases.

Ital J Dermatol Venereol

Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab.

J Allergy Clin Immunol

Trial of nemolizumab in moderate-to-severe prurigo nodularis.

N Engl J Med

Modulation of neuroimmune and epithelial dysregulation in patients with moderate to severe prurigo nodularis treated with nemolizumab.

JAMA Dermatol

Phase 3 trial of nemolizumab in patients with prurigo nodularis.

Validation of the Peak Pruritus Numerical Rating Scale as a patient-reported outcome measure in prurigo nodularis.

Dermatol Ther (Heidelb)

Impact of itch on sleep disturbance in patients with prurigo nodularis.

Acta Derm Venereol

Retrospective analysis of data from an itch center: integrating validated tools in the electronic health record.

Health-related quality of life and economic burden of prurigo nodularis.

The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries.

The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries.

Chronic pruritus of unknown origin: clinical profile and disease-related burden.

Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.

Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice.

Nat Immunol

A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1.

sensory neurons co-opt classical immune signaling pathways to mediate chronic itch.

Cell

Interleukin-4 and interleukin-13 evoke scratching behaviour in mice.

Exp Dermatol

Dermal periostin: a new player in itch of prurigo nodularis.

Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study.

Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.

Trial of nemolizumab and topical agents for atopic dermatitis with pruritus.

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.

Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis.

Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.

Nat Med

Prurigo nodularis (PN) is a chronic and debilitating skin condition, characterized by intense itch with multiple nodular lesions. Nemolizumab demonstrated significant improvements in itch and skin nodules in adults with moderate to severe PN in a previous 16-week phase 3 study (OLYMPIA 2).
To assess the efficacy and occurrence of adverse events in adults with moderate to severe PN treated with nemolizumab vs those receiving placebo.
OLYMPIA 1 was a multicenter, placebo-controlled, phase 3 randomized clinical trial, conducted from August 2020 to March 2023 at 77 centers across 10 countries in adults with moderate to severe PN (at least 20 nodules and an Investigator's Global Assessment [IGA] score ≥3) and Peak Pruritus Numerical Rating Scale (PP-NRS) score of at least 7.0; consisted of screening (up to 4 weeks), 24-week treatment, and 8-week follow-up periods.
Patients were randomized (2:1) to nemolizumab monotherapy, 30 mg or 60 mg (depending on baseline weight of less than 90 kg vs 90 kg or greater, respectively), or matching placebo administered every 4 weeks for 24 weeks.
The primary end points were the proportion of patients with itch response (≥4-point improvement from baseline in weekly average PP-NRS) and IGA success (score of 0/1 [clear/almost clear] and 2-grade or more improvement from baseline) at week 16.
Of 286 patients (mean [SD] age, 57.5 [13.0] years; mean [SD] body weight, 85.0 [20.7] kg; 166 [58.0%] female), 190 were randomized to receive nemolizumab, and 96 were randomized to placebo. A significantly greater proportion of patients assigned to nemolizumab vs placebo achieved itch response (111/190 [58.4%] vs 16/96 [16.7%]; Δ, 40.1% [95% CI, 29.4%-50.8%]; P < .001) and IGA success (50/190 [26.3%] vs 7/96 [7.3%]; Δ, 14.6% [95% CI, 6.7%-22.6%]; P = .003) at week 16. At week 24, the proportion of patients with itch response was 58.3% vs 20.4% (Δ, 38.7% [95% CI, 27.5%-49.9%]) in the ad hoc analysis, and IGA success was 58/190 (30.5%) vs 9/96 (9.4%) (Δ, 19.2% [95% CI, 10.3%-28.1%]) in the nemolizumab-treated vs placebo group. During the treatment period, 134 patients (71.7%) receiving nemolizumab vs 62 patients (65.3%) receiving placebo had at least 1 adverse event; most events were of mild to moderate severity.
In this randomized clinical trial, nemolizumab monotherapy led to clinically meaningful and statistically significant improvements in core signs and symptoms of PN.
ClinicalTrials.gov Identifier: NCT04501666.

Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.

Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis

Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis

Clinical Summary

What was studied

Key findings

Study limitations

Clinical implications

Related Questions